Читать книгу Nanobiotechnology in Diagnosis, Drug Delivery and Treatment - Группа авторов - Страница 59

Liposomes are nanostructures comprised of a lipid bilayer membrane surrounding an aqueous interior (Gaur et al. 2008). They may carry hydrophilic drugs inside the capsule or lipophilic drugs inserted into the phospholipid bilayer (Figure 3.1). Liposomes possess good biocompatibility because the raw materials that compose them are natural phospholipids, sterols, or glycerolipids, thus they may interfere with the cell membrane (Laroui et al. 2011; He et al. 2019). Liposome‐based nanoparticles are commonly used nanoparticles for delivering small peptides, nucleic acids, and proteins in nanoplatform drug delivery (Huynh et al. 2009). They behave as a modified release system (Laroui et al. 2011). To date, several nanoliposomes have been developed for therapy of colorectal cancer (CRC), namely Doxorubicin (Doxil^®) or Marqibo^® which are examples of Food and Drug Administration (FDA)‐approved nanoliposomes for chemotherapy of CRC (Barenholz 2012; Stang et al. 2012; Allen and Cullis 2013). Thermo‐sensitive liposome doxorubicin (Thermodox^®) is another promising nanoliposomal drug for colorectal liver metastases in combination with radiofrequency ablation. This nanoliposome with doxorubicin formulation releases the drug upon a mild hyperthermic trigger and can deliver 25‐fold more doxorubicin into tumors than IV doxorubicin does (Stang et al. 2012).